Business Description
Biosyent Inc
NAICS : 325412
SIC : 3741
ISIN : CA0906901081
Description
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.74 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.11 | |||||
| Interest Coverage | 563.48 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 12.78 | |||||
| Beneish M-Score | 1.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15 | |||||
| 3-Year EBITDA Growth Rate | 18.6 | |||||
| 3-Year EPS without NRI Growth Rate | 23.3 | |||||
| 3-Year FCF Growth Rate | -7.9 | |||||
| 3-Year Book Growth Rate | 12.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 20.38 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.44 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.87 | |||||
| 9-Day RSI | 48.21 | |||||
| 14-Day RSI | 51.43 | |||||
| 6-1 Month Momentum % | 12.5 | |||||
| 12-1 Month Momentum % | 24.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.92 | |||||
| Quick Ratio | 3.11 | |||||
| Cash Ratio | 2.43 | |||||
| Days Inventory | 286.4 | |||||
| Days Sales Outstanding | 36.01 | |||||
| Days Payable | 252.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.55 | |||||
| Dividend Payout Ratio | 0.29 | |||||
| Forward Dividend Yield % | 1.55 | |||||
| 5-Year Yield-on-Cost % | 1.55 | |||||
| 3-Year Average Share Buyback Ratio | 2.9 | |||||
| Shareholder Yield % | 3.44 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.42 | |||||
| Operating Margin % | 101.24 | |||||
| Net Margin % | 20.6 | |||||
| FCF Margin % | 5.63 | |||||
| ROE % | 20.12 | |||||
| ROA % | 16.93 | |||||
| ROIC % | 186.4 | |||||
| ROC (Joel Greenblatt) % | 169.06 | |||||
| ROCE % | 25.88 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.43 | |||||
| Forward PE Ratio | 14.56 | |||||
| PE Ratio without NRI | 19.43 | |||||
| Shiller PE Ratio | 26.56 | |||||
| Price-to-Owner-Earnings | 21.27 | |||||
| PEG Ratio | 2.02 | |||||
| PS Ratio | 4.01 | |||||
| PB Ratio | 3.61 | |||||
| Price-to-Tangible-Book | 4.23 | |||||
| Price-to-Free-Cash-Flow | 71.4 | |||||
| Price-to-Operating-Cash-Flow | 20.53 | |||||
| EV-to-EBIT | 12.33 | |||||
| EV-to-EBITDA | 11.74 | |||||
| EV-to-Revenue | 3.37 | |||||
| EV-to-Forward-Revenue | 2.79 | |||||
| EV-to-FCF | 60.47 | |||||
| Price-to-Projected-FCF | 1.36 | |||||
| Price-to-DCF (Earnings Based) | 1.02 | |||||
| Price-to-DCF (FCF Based) | 3.96 | |||||
| Price-to-Median-PS-Value | 0.89 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.45 | |||||
| Price-to-Graham-Number | 1.91 | |||||
| Price-to-Net-Current-Asset-Value | 6.88 | |||||
| Price-to-Net-Cash | 15 | |||||
| Earnings Yield (Greenblatt) % | 8.11 | |||||
| FCF Yield % | 1.46 | |||||
| Forward Rate of Return (Yacktman) % | 16.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Biosyent Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 34.509 | ||
| EPS (TTM) (C$) | 0.599 | ||
| Beta | 0.47 | ||
| Volatility % | 17.02 | ||
| 14-Day RSI | 51.43 | ||
| 14-Day ATR (C$) | 0.271679 | ||
| 20-Day SMA (C$) | 11.543 | ||
| 12-1 Month Momentum % | 24.31 | ||
| 52-Week Range (C$) | 8.24 - 12.13 | ||
| Shares Outstanding (Mil) | 11.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biosyent Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biosyent Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biosyent Inc Frequently Asked Questions
What is Biosyent Inc(TSXV:RX)'s stock price today?
The current price of TSXV:RX is C$11.55. The 52 week high of TSXV:RX is C$12.13 and 52 week low is C$8.24.
When is next earnings date of Biosyent Inc(TSXV:RX)?
The next earnings date of Biosyent Inc(TSXV:RX) is 2025-03-13 Est..
Does Biosyent Inc(TSXV:RX) pay dividends? If so, how much?
The Dividend Yield % of Biosyent Inc(TSXV:RX) is 1.55% (As of Today), Highest Dividend Payout Ratio of Biosyent Inc(TSXV:RX) was 0.3. The lowest was 0.09. And the median was 0.2. The Forward Dividend Yield % of Biosyent Inc(TSXV:RX) is 1.55%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers